Ask the questions that change your outcome
GLP-1 consultations are often brief — 15 to 30 minutes for an initial visit. That's enough time if you come prepared, but not enough to wing it. These five questions cut through the noise and surface the information that actually affects your treatment experience.
1. "Which medication and formulation do you recommend for me, and why?"
This matters because the GLP-1 landscape in 2026 includes multiple options: injectable semaglutide (Wegovy), injectable tirzepatide (Zepbound), oral semaglutide (Wegovy pill), oral orforglipron (Foundayo), and compounded versions of semaglutide and tirzepatide. Each has different efficacy profiles, side effect patterns, and costs.
A good provider should explain why they're recommending a specific medication for your situation — not just default to whatever they have in stock. The recommendation should account for your health history, insurance coverage, needle comfort level, and weight loss goals. If your provider prescribes without explaining their reasoning, ask.
2. "What's the titration schedule, and what happens if I can't tolerate a dose increase?"
Every GLP-1 medication uses a gradual dose escalation schedule to minimize side effects. Semaglutide steps through five doses over 16–20 weeks; tirzepatide through six doses. The key question is whether your provider follows a rigid schedule or adjusts based on your response.
The answer you want to hear: "We'll follow the standard schedule, but if you're having significant side effects at any dose, we'll extend the time at that level before increasing. The schedule is a guide, not a mandate." Research shows that slower titration reduces discontinuation rates by approximately 40%. A provider who pushes you to escalate on schedule despite persistent side effects is prioritizing protocol over your experience.
3. "What should I do if I experience severe nausea or other side effects?"
Nausea is the most common GLP-1 side effect, reported by 44% of participants in the STEP 1 trial. Most cases are mild and resolve during titration, but some patients experience nausea severe enough to affect daily functioning. You need a plan before it happens.
Your provider should offer specific guidance: eat smaller meals, avoid high-fat foods, stay hydrated, and consider over-the-counter anti-nausea options. They should also explain when to contact them versus when to manage independently, and whether they have a same-day or next-day response channel for urgent side-effect concerns.
4. "What monitoring will you do during treatment?"
GLP-1 treatment isn't a "set it and forget it" prescription. Responsible monitoring includes periodic check-ins (monthly or every other month at minimum during the first year), weight tracking to assess response, lab work at intervals (metabolic panel, liver enzymes, and HbA1c if diabetic), and assessment for gallbladder symptoms, especially during rapid weight loss.
If your provider's monitoring plan consists of "let us know if you have problems," that's insufficient. You want proactive check-ins, not just reactive troubleshooting.
5. "What happens when I stop the medication?"
This is the question most patients don't ask — and most providers don't volunteer. Clinical data shows that approximately two-thirds of weight lost on GLP-1 medications is regained within one year of stopping treatment. The STEP 1 extension study found participants regained about 67% of their weight loss by week 120 after discontinuation.
This doesn't mean GLP-1 treatment is pointless — it means you need a realistic plan for long-term management. Your provider should discuss whether you're likely to need ongoing treatment, what a maintenance dose looks like (some patients maintain results at lower doses), and what lifestyle strategies can help sustain results if you discontinue.